سعر نوستيفيكس 0.5مجم 2 قرص 2024

Nostifix 0.5 mg tablets (Marcyrl Co., Egypt): cabergoline 0.5 mg, an ergot-derived dopamine D2 agonist that inhibits prolactin secretion; pack of 2 tablets.

• Hyperprolactinaemic disorders, idiopathic or due to pituitary adenomasPopulation: AdultsDailyMed (NLM)
• Dysfunctions associated with hyperprolactinaemia (amenorrhoea, oligomenorrhoea, anovulation, galactorrhoea) and prolactin-secreting pituitary adenomasPopulation: Adultselectronic Medicines Compendium (eMC) / MHRA
• Inhibition of physiological lactation after delivery, and suppression of established lactationPopulation: Postpartum womenelectronic Medicines Compendium (eMC) / MHRA

• Most common (>10%): nausea, headache, dizziness.International label, same formulation · DailyMed (NLM)
• Very common: valvulopathy and related disorders, headache, dizziness/vertigo, nausea, dyspepsia, gastritis, abdominal pain; common: somnolence, depression, postural hypotension, hot flushes, constipation, vomiting.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA

• Hypersensitivity to cabergoline or any ergot alkaloid; history of pulmonary, pericardial or retroperitoneal fibrotic disorders; hepatic insufficiency; toxaemia of pregnancy; coadministration with antipsychotics or history of puerperal psychosis; for long-term treatment, cardiac valvulopathy on echocardiography.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA
• Uncontrolled hypertension; hypersensitivity to ergot derivatives; history of cardiac valvular disorders or pericardial fibrosis; history of pleural, pulmonary or retroperitoneal fibrotic disorders.International label, same formulation · DailyMed (NLM)

• Cardiac valvulopathy and pericardial fibrosis: echocardiogram before treatment and every 6-12 months; discontinue on new valvular regurgitation/restriction or pericarditis. Monitor for pleural, pulmonary and retroperitoneal fibrosis.International label, same formulation · DailyMed (NLM)
• Orthostatic hypotension (greater with other antihypertensives); impulse control disorders (gambling, hypersexuality, compulsive spending/eating) - consider dose reduction or stopping.International label, same formulation · DailyMed (NLM)

• Dopamine D2 antagonists (phenothiazines, butyrophenones, thioxanthenes, metoclopramide)Not recommended; may reduce the prolactin-lowering effect.DailyMed (NLM)
• Macrolide antibiotics (e.g. erythromycin)Should not be used together because of increased cabergoline bioavailability.electronic Medicines Compendium (eMC) / MHRA

• If conception occurs, discontinue if risks to mother or fetus outweigh benefits; generally avoid dopamine agonists in pregnancy and postpartum, especially with pregnancy-induced hypertension or pre-eclampsia; case reports show no clear association with major birth defects.International label, same formulation · DailyMed (NLM)
• No adequate studies in pregnant women; in a 12-year observational study of 256 pregnancies, 6.6% ended in major congenital malformations or abortion (no control group); use only if clearly indicated; women planning pregnancy should stop cabergoline beforehand because of its long half-life.International label, same formulation · electronic Medicines Compendium (eMC) / MHRA
• Not recommended in postpartum women who are breastfeeding or planning to breastfeed.International label, same formulation · DailyMed (NLM)

• Cabergoline: Dopaminergic ergoline derivative that directly stimulates D2 dopamine receptors on pituitary lactotrophs, giving potent, long-lasting inhibition of prolactin secretion.